Your Top 100 most-cited badge
A badge for your website, a sentence for your CV, and a permanent page where anyone can check the rank.
The article
166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study
P. Schmid, K.H. Jung, Piotr Jan Wysocki, Jacek Jassem, C.X. Ma, R. Fernandes and 5 more
- Rank
- 89 of 3,616
- Percentile
- top 2.5%
- Where
- Annals of Oncology, 2022
- Citations
- 45
From the 2022 list, OpenAlex counts as of 2026-10-29.
Prefer not to be listed? The same link lets you withhold your name on every list; the article stays, your name does not. Questions: team@avidnote.com.